Federal Circuit denies Novartis’ bid to halt generics

Bid to stay invalidity decision pending a SCOTUS appeal fails | Patent covers a multiple sclerosis drug | Company could take $300m hit if generics are launched.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Why Novartis lost its treatment dispute with Teva

17 January 2023 The pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP.

Americas

Generic maker hits back at Novartis stay bid

6 October 2022 HEC claims the delay would buy Novartis months of “unjustified monopoly profits” | Response says the Swiss big pharma company makes $3.8m a day from multiple sclerosis drug at issue.

Americas

Swiss pharma company reveals SCOTUS appeal plans

22 September 2022 Federal Circuit denies petition to rehear dispute over multiple sclerosis medicine | Company will petition highest court over invalidity ruling.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Federal Circuit denies Novartis’ bid to halt generics

More on this story

Editor's picks

Editor's picks

More features